B Cell Lymphoma
From the Journals
CAR T-cell therapy neurotoxicity linked to NfL elevations
Even prior to CAR T-cell therapy, patients developing related neurotoxic complications show elevated markers of neuronal injury.
From the Journals
Phase 3 data: Zanubrutinib bests standard CLL treatment
Results could spur FDA approval as frontline therapy.
From the Journals
Heed cardiac risk of BTKis for CLL
New consensus statement warns about cardiac risk of using BTKis, but a cardio-oncologist specialist questions its conclusions.
Feature
Drug shortages plague hematology, but preparedness helps
The plight of desperate patients is getting attention – and some remedies.
News
FDA approves liso-cel as second-line therapy for LBCL
Liso-cel could now become a “new standard of care for patients after failure of first-line therapy,” offering significantly improved outcomes for...
Conference Coverage
Novel gene therapy offers hope for some lymphomas
Novel CAR T-cell product shows promise for second-line treatment of relapsed and refractory lymphoma patients in a pilot study.
Conference Coverage
Glofitamab prevails against r/r DLBCL
Additional longer-term data showed a strong safety profile and promising long-term remission.
Latest News
‘Exciting’ new gene therapy yields promising results
A single dose of CAR-T cell therapy evoked a beneficial response in patients with relapsed or refractory non-Hodgkin lymphoma.
Feature
Third-generation Black woman physician makes cancer research history
African American surgeon helped found ASCO and collaborated with her father to achieve lasting breakthroughs in chemotherapy.
Feature
Ex–hospital porter a neglected giant of cancer research
An Indian immigrant who once emptied bedpans in a Boston hospital went on to become the “father of chemotherapy.”
Feature
Repurposed drug could revolutionize stem cell transplantation
Abatacept to prevent for acute graft-versus-host disease is a game changer for patients receiving hematopoietic stem cell transplants who lack...